The data, from more than 8,000 users, was published in the medical journal Diabetes Technology & Therapeutics.
San Diego-based Tandem said the study showed a 45% relative risk reduction in hypoglycemia and a 71% relative risk reduction in hypoglycemic events, both of which exceeded reductions observed in the controlled pivotal study for Basal-IQ technology.
The t:slim X2 pump is designed to monitor glucose without fingersticks and features a touchscreen, rechargeable battery, wireless technology and USB connectivity. Tandem said the pump is 38% smaller than other insulin pumps and holds up to 300 units of insulin.
The device was established as as the first in a new category of devices called ‘Alternate Controller Enabled Infusion Pumps’ or ACE pumps in February. The t:slim X2 pump was launched in the U.S. in August 2018 and approved in Canada the following October.
“This data supports the overwhelmingly positive feedback we hear from our customers using Basal-IQ technology and the clinical improvement people often report experiencing after initiating its use,” president & CEO John Sheridan said in prepared remarks. “We continue to hear that our t:slim X2 insulin pump with Basal-IQ technology is extremely simple to learn and use, which is a core tenet across all of our products, and we believe this leads to greater customer satisfaction and improved clinical outcomes.”
Shares of TNDM were up 0.9% at $61.74 per share in midday trading today.